Beta Bionics, Inc. - Common Stock (BBNX)

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $18.75 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) --

LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) of the November 3, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

San Diego, California--(Newsfile Corp. - September 14, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class...

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

Law Offices of Howard G. Smith reminds investors of the upcoming November 3, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Levi & Korsinsky, LLP alerts investors in Beta Bionics, Inc. (NASDAQ: BBNX) that Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider are named as individual defendants in a pending securities class action asserting control person and primary liability claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, on behalf of purchasers between July 30, 2025 and February 24, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 3, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) of the November 3, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW ORLEANS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) --

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lead plaintiff motion.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.